Tangential flow filtration as a novel approach for fluorescent tracer purification and production up-scaling: cetuximab-800CW and ustekinumab-800CW as a proof-of-concept. (PubMed, MAbs) - Oct 9, 2026 - "Ustekinumab-800CW was stable up to 24 months at 2-8°C. Together, this demonstrates the feasibility of using TFF for clinical-grade fluorescent tracer manufacturing under GMP conditions."
Journal
|
|
Bahez Gareb; Bart G J Dekkers; Hans H Westra; Henrik K Huizinga; Jacoba van Zanten; Marjolijn N Lub-de Hooge; Pauline Koopmans; Rosalie J van Dijken; Wouter B Nagengast
|